ArticleOncotarget2018
An improved method for culturing patient-derived colorectal cancer spheroids.
Article in Oncotarget, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed.
- Comprehensive Colorectal Cancer Stem Cell Transcriptomic Signatures That Can Predict Patient Prognostic Outcomes.Cancer science · 2026Article
- Zebrafish Avatar-test forecasts clinical response to chemotherapy in patients with colorectal cancer.Nature communications · 2024Article
- Spheroids and organoids derived from colorectal cancer as tools forExploration of targeted anti-tumor therapy · 2024Review
- Toward reproducible tumor organoid culture: focusing on primary liver cancer.Frontiers in immunology · 2024Review
- Article
- Exploring the promising potential of induced pluripotent stem cells in cancer research and therapy.Molecular cancer · 2023Review
- Housing conditions affect enterocyte death mode and turnover rate in mouse small intestine.Scientific reports · 2023Article
- Novel and efficient method for culturing patient-derived gastric cancer stem cells.Cancer science · 2023Article
- Strategies to capitalize on cell spheroid therapeutic potential for tissue repair and disease modeling.NPJ Regenerative medicine · 2022Review
- Targeting Asparagine Synthetase in Tumorgenicity Using Patient-Derived Tumor-Initiating Cells.Cells · 2022Article
- How inclusive are cell lines in preclinical engineered cancer models?Disease models & mechanisms · 2022Article
- Patient-derived tumor spheroid cultures as a promising tool to assist personalized therapeutic decisions in breast cancer.Translational cancer research · 2022Article
- The therapeutic potential of multiclonal tumoricidal T cells derived from tumor infiltrating lymphocyte-1derived iPS cells.Communications biology · 2021Article
- Challenges of applying multicellular tumor spheroids in preclinical phase.Cancer cell international · 2021Review
- Stem cells as therapeutic targets in colorectal cancer.Personalized medicine · 2021Review
- A 3D View of Colorectal Cancer Models in Predicting Therapeutic Responses and Resistance.Cancers · 2021Review
- Standardizing Patient-Derived Organoid Generation Workflow to Avoid Microbial Contamination From Colorectal Cancer Tissues.Frontiers in oncology · 2021Article
- Article
- Review
- Zebrafish Avatars towards Personalized Medicine-A Comparative Review between Avatar Models.Cells · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recent advances allowed culturing and examination of patient-derived colorectal cancer (PD-CRC) cells as organoids or spheroids. To be applied to practical personalized medicine, however, current methods still need to be strengthened for higher efficiency. Here we report an improved method to propagate PD-CRC tumor initiating cells (TICs) in spheroid culture. We established > 100 cancer spheroid lines derived from independent colorectal cancer patients employing a serum-containing medium with additional inhibitors, Y27632 and SB431542. Because colorectal cancer spheroids showed wide-range growth rates depending on the patient tumors, we searched for supplementary factors that accelerated proliferation of slow-growing CRC-TIC spheroids. To this end, we introduced a convenient growth-monitoring method using a luciferase reporter. We found that epidermal growth factor (EGF) and/or basic fibroblast growth factor (bFGF) were critical for steady propagation of a subset of CRC-TIC spheroids carrying the wild-type
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.